Vantage logo

Should gene therapy patients be asked to pay?

The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…

Vantage logo

Solid guns for Sarepta

Solid Biosciences should soon find out if its DMD gene therapy, SGT-001, could compete with Sarepta’s.